Literature DB >> 23969900

Non-B, non-C hepatocellular carcinoma (Review).

Hiroki Nishikawa1, Yukio Osaki.   

Abstract

Although most hepatocellular carcinoma (HCC) is related to viral infection, there is a substantial population of HCC patients (5-20%) who are negative for both markers of hepatitis B virus and hepatitis C virus infection [non-B, non-C (NBNC) hepatitis] in Japan and the incidence of NBNC-HCC has recently tended to increase. The most common cause of liver disease in developed countries is non‑alcoholic fatty liver disease (NAFLD), which includes non‑alcoholic steatohepatitis (NASH) and its related complications. Increased body mass index and diabetes mellitus are associated with developing NAFLD and NASH, which is a severe form of NAFLD. Furthermore, increasing clinical evidence supports the fact that NAFLD and NASH can progress to liver cirrhosis and even HCC. A detailed understanding of the epidemiology, etiology, molecular mechanism, clinical features and prognosis of NBNC-HCC could improve our screening and therapy of this disease. In this review, we primarily focus on clinical aspects of NBNC-HCC and refer to our current knowledge of this cancer.

Entities:  

Mesh:

Year:  2013        PMID: 23969900     DOI: 10.3892/ijo.2013.2061

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  25 in total

1.  Outcomes after hepatectomy of patients with positive HBcAb Non-B Non-C hepatocellular carcinoma compared to overt hepatitis B virus hepatocellular carcinoma.

Authors:  Shan-Shan Wu; Quan-Yuan Shan; Wen-Xuan Xie; Bin Chen; Yang Huang; Yu Guo; Xiao-Yan Xie; Ming-De Lu; Bao-Gang Peng; Ming Kuang; Shun-Li Shen; Wei Wang
Journal:  Clin Transl Oncol       Date:  2019-06-06       Impact factor: 3.405

2.  Risk Assessment of Hepatocellular Carcinoma in General Population by Liver Stiffness in Combination with Controlled Attenuation Parameter using Transient Elastography: A Cross Sectional Study.

Authors:  Takaaki Sugihara; Masahiko Koda; Tomomitsu Matono; Kinya Okamoto; Yoshikazu Murawaki; Hajime Isomoto; Shiho Tokunaga
Journal:  Yonago Acta Med       Date:  2017-06-26       Impact factor: 1.641

3.  Three risk factors for pulmonary metastasectomy in patients with hepatocellular carcinoma.

Authors:  Akifumi Nakamura; Minoru Esaki; Kazuo Nakagawa; Keisuke Asakura; Yoji Kishi; Satoshi Nara; Kazuaki Shimada; Shun-Ichi Watanabe
Journal:  Gen Thorac Cardiovasc Surg       Date:  2019-02-28

4.  A nomogram for predicting the risk of postoperative recurrence of hepatitis B virus-related hepatocellular carcinoma in patients with high preoperative serum glutamyl transpeptidase.

Authors:  Jia-Si Zhang; Zhi-Heng Wang; Xing-Gang Guo; Ji Zhang; Jun-Sheng Ni
Journal:  J Gastrointest Oncol       Date:  2022-02

5.  Risk factors for non-alcoholic fatty liver disease are common in patients with non-B non-C hepatocellular carcinoma in India.

Authors:  Deepu David; Anantharam Raghavendran; Ashish Goel; C Bharath Kumar; Thomas Alex Kodiatte; Deepak Burad; Priya Abraham; Banumathi Ramakrishna; Philip Joseph; Jeyamani Ramachandran; C E Eapen
Journal:  Indian J Gastroenterol       Date:  2017-10-04

6.  Pre- and Postoperative Models for Prediction of Recurrence in Non-B, Non-C Hepatocellular Carcinoma.

Authors:  Kongying Lin; Qizhen Huang; Lei Wang; Jianxing Zeng; Zongren Ding; Hongzhi Liu; Jun Fu; Pengfei Guo; Zhenwei Chen; Yongyi Zeng; Weiping Zhou; Jingfeng Liu
Journal:  Front Oncol       Date:  2021-02-18       Impact factor: 6.244

7.  Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan: a retrospective analysis.

Authors:  Takamasa Ohki; Koki Sato; Mari Yamagami; Daisaku Ito; Tomoharu Yamada; Koki Kawanishi; Kentaro Kojima; Michiharu Seki; Nobuo Toda; Kazumi Tagawa
Journal:  Clin Drug Investig       Date:  2015-11       Impact factor: 2.859

8.  Synergistic antitumor effect of Doxorubicin and tacrolimus (FK506) on hepatocellular carcinoma cell lines.

Authors:  Francesca Capone; Eliana Guerriero; Angela Sorice; Giovanni Colonna; Gabriella Storti; Jessica Pagliuca; Giuseppe Castello; Susan Costantini
Journal:  ScientificWorldJournal       Date:  2014-02-20

9.  Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review.

Authors:  Yukio Osaki; Hiroki Nishikawa
Journal:  Hepatol Res       Date:  2014-07-18       Impact factor: 4.288

10.  Clinical implication of performance status in patients with hepatocellular carcinoma complicating with cirrhosis.

Authors:  Hiroki Nishikawa; Ryuichi Kita; Toru Kimura; Yoshiaki Ohara; Azusa Sakamoto; Sumio Saito; Norihiro Nishijima; Akihiro Nasu; Hideyuki Komekado; Yukio Osaki
Journal:  J Cancer       Date:  2015-02-26       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.